LGND - At Ligand Pharmaceuticals Todd C Davis Chooses To Exercise Options Resulting In $252K | Benzinga
A significant insider transaction involving the exercise of company stock options was reported on March 27, by Todd C Davis, Chief Executive Officer at Ligand Pharmaceuticals (NASDAQ:LGND), as per the latest SEC filing.
What Happened: Disclosed in a Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission, Davis, Chief Executive Officer at Ligand Pharmaceuticals, executed a strategic derivative sale. This involved exercising stock options for 16,015 shares of LGND, resulting in a transaction value of $252,004.
Currently, Ligand Pharmaceuticals shares are trading up 2.61%, priced at $73.13 during Thursday's morning. This values Davis's 16,015 shares at $252,004.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ligand Pharmaceuticals's Financial Performance
Decline in Revenue: Over the 3 months period, Ligand Pharmaceuticals faced challenges, resulting in a decline of approximately -44.22% in revenue growth as ...